Also some novel biomarkers were investigated to predict the survival outcome of PSC, such as CD8+ tumor-infiltrating lymphocytes, the epithelial−mesenchymal transition transcription factors (Twist1), the change of neutrophil-to-lymphocyte ratio, KRAS mutations and c-MET overexpression (32–36). This evidence concerns the gene KRAS and neoplasm.